DGAP-News

Epigenomics AG: Epigenomics and BioChain Announce Approval of Epi proColon(R) in China - Seite 2

forward to bringing this effective and non-invasive option to the people
eligible for CRC screening in our country."

"We are extremely pleased to announce the approval of Epi proColon(R) in
the important Chinese market. BioChain has been incredibly efficient in
driving this approval process in a very short time. We now look forward to
working closely with our partner BioChain on the launch of this very
important diagnostic tool," added Epigenomics' CEO/CFO Dr. Thomas Taapken.
"We are convinced that our test will help to reduce the mortality and costs
of care associated with CRC in China through the early identification of
the disease."

- Ends -

Contact Epigenomics AG

Antje Zeise, Manager IR | PR
Epigenomics AG
Geneststraße 5
10829 Berlin
Tel [phone]
[e-mail]
www.epigenomics.com
For US press inquiries:

Epigenomics, Inc.
20271 Goldenrod Lane, Suite 2027
Germantown, Maryland 20876
[e-mail]

About Epigenomics

Epigenomics (www.epigenomics.com) is a molecular diagnostics company
developing and commercializing a pipeline of proprietary products for
cancer. The Company's products enable doctors to diagnose cancer earlier
and more accurately, leading to improved outcomes for patients.
Epigenomics' lead product, Epi proColon(R), is a blood-based test for the
early detection of colorectal cancer, which is currently marketed in
Europe, and has received approval by the Chinese Food and Drug
Administration for China and is under regulatory review by the U.S. Food
and Drug Administration (FDA). Additionally, the Company markets its tissue
assay for use in lung cancer diagnosis, Epi proLung(R), in Europe. The
Company's technology and products have been validated through multiple
partnerships with leading global diagnostic companies and testing
laboratories. Epigenomics is an international company with operations in
Europe and the U.S.A.

About BioChain

BioChain (www.biochain.com, www.biochainbj.com) is a manufacturer of Life
Sciences tools and the pioneer of molecular genetics diagnostics in the US
and China. It is also the owner and operator of an independent reference
laboratory, equivalent of a CLIA lab, in China - Beijing BioChain Medical
Laboratory (BBML). BBML is unique in that it focuses on the application of
molecular diagnostics technologies and products. BBML is located in the
economic development zone of Beijing, China. Through BBML, BioChain is
committed to the application of the cutting edge "omics" technologies in
the areas of reproductive health and cancer diagnosis. BBML offers
comprehensive services to its customers in China with a list of cellular